Compare Stocks → IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:APRENASDAQ:DMACOTCMKTS:IGXTNASDAQ:MRKR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$2.40+7.1%$1.57$0.76▼$14.00$9.72M1.485.42 million shs1.09 million shsAPREAprea Therapeutics$5.73-2.1%$6.52$2.78▼$8.85$31.11M1.0331,167 shs838 shsDMACDiaMedica Therapeutics$2.57+8.4%$2.87$1.50▼$4.75$97.56M1.6943,038 shs32,118 shsIGXTIntelGenx Technologies$0.18+5.9%$0.16$0.09▼$0.26$31.44M2.4388,438 shs46,967 shsMRKRMarker Therapeutics$4.34-1.4%$4.26$0.76▼$9.68$38.63M1.521,111 shs6,895 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals-14.18%+98.23%+41.77%+67.16%-69.14%APREAprea Therapeutics-3.88%-5.62%-7.92%+8.99%+40.74%DMACDiaMedica Therapeutics-0.84%-12.55%-21.78%-14.13%+48.13%IGXTIntelGenx Technologies+5.88%+3.45%+8.89%+5.88%-6.49%MRKRMarker Therapeutics-0.90%-4.97%-0.68%+1.62%+289.38%IRS Loophole Gives Americans An Escape From Inflation (Ad)In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.Request your info kit on gold nowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals0.815 of 5 stars0.05.00.00.02.60.80.6APREAprea Therapeutics3.2103 of 5 stars3.55.00.00.01.73.30.6DMACDiaMedica Therapeutics0.9486 of 5 stars3.53.00.00.01.10.00.0IGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/AAPREAprea Therapeutics3.00Buy$15.50170.51% UpsideDMACDiaMedica Therapeutics3.00Buy$7.00172.37% UpsideIGXTIntelGenx TechnologiesN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ADIL, IGXT, APRE, DMAC, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/AAPREAprea Therapeutics$580K53.64N/AN/A$4.54 per share1.26DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AIGXTIntelGenx Technologies$1.04M30.23N/AN/A($0.07) per share-2.57MRKRMarker Therapeutics$3.31M11.67N/AN/A$1.58 per share2.75Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)APREAprea Therapeutics-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/AMRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)Latest ADIL, IGXT, APRE, DMAC, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APREAprea Therapeutics-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million 3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90APREAprea TherapeuticsN/A5.135.13DMACDiaMedica TherapeuticsN/A19.2719.27IGXTIntelGenx TechnologiesN/A0.410.40MRKRMarker TherapeuticsN/A5.575.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%APREAprea Therapeutics34.19%DMACDiaMedica Therapeutics10.12%IGXTIntelGenx TechnologiesN/AMRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%APREAprea Therapeutics20.90%DMACDiaMedica Therapeutics7.20%IGXTIntelGenx Technologies62.67%MRKRMarker Therapeutics24.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals164.05 million3.47 millionNo DataAPREAprea Therapeutics95.43 million4.30 millionNo DataDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableIGXTIntelGenx Technologies4174.66 million65.20 millionNot OptionableMRKRMarker Therapeutics678.90 million6.76 millionNot OptionableADIL, IGXT, APRE, DMAC, and MRKR HeadlinesSourceHeadlineVolunteers needed for National Historic Marker Dayromesentinel.com - April 16 at 11:03 AMJennett Marker Named Human Resources Manager For Chore-Timetimesuniononline.com - April 13 at 7:52 AMHaliwa-Saponi Indian Tribe to be featured on Highway Historical Markerwarrenrecord.com - April 11 at 12:59 PMMarker Therapeutics Inc (MRKR)investing.com - April 10 at 8:50 PMWin an overnight stay with afternoon tea at Anantara The Marker Dublin Hotel.irishtimes.com - April 10 at 3:36 AMMicroRNA Liquid Biopsy Test Shows Potential for Early Pancreatic Cancer Detectionprecisionmedicineonline.com - April 9 at 5:13 PMPutnam Marker Honoring Warner Sisters Restored At Foundry Point Parkmsn.com - April 9 at 5:13 PMSite of former Allentown State Hospital to receive Official State Historical Markerwfmz.com - April 9 at 5:13 PMRobert Edgar Sherrill Memorial Marker Will Be Dedicated April 25chattanoogan.com - April 9 at 12:13 PMCinco de Mayo Margarita Battle at The Marker Key West Harbor Resortbocaratonobserver.com - April 9 at 12:13 PMPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignanciesglobenewswire.com - April 8 at 7:00 AMVolunteers needed April 26 for National Historic Marker Daywestsidenewsny.com - April 7 at 1:24 PMMorrisound Recording Awarded Historical Marker For Contributions To Extreme Metal, Music Industrymetalinjection.net - April 3 at 2:36 PMGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular Diseasesfinance.yahoo.com - April 3 at 2:36 PMMouse Models and Markers for Cerebral Amyloid Angiopathy, ARIAalzforum.org - March 28 at 5:52 PMThe Andy Westcott Band Concert at The Marker Key West Harbor Resortbocaratonobserver.com - March 27 at 9:34 AMMiddle Passage Marker in Port Arthur commemorates ancestors, provides history of local slave tradepanews.com - March 26 at 5:22 AMMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31Mmsn.com - March 26 at 5:22 AMMarker Therapeutics Reports Year-End 2023 Corporate and Financial Resultsglobenewswire.com - March 25 at 5:45 PMLegends & Lore Marker program accepting grant applicationsthedailynewsonline.com - March 23 at 2:55 AMMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conferenceglobenewswire.com - March 22 at 12:30 PMJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party Leadermsn.com - March 22 at 3:03 AMMarker dedication reset for Temple cemeterytdtnews.com - March 20 at 8:51 PMSpring Break Pool Party with DJ BUGGY at The Markerbocaratonobserver.com - March 19 at 3:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideeBay Steadily Climbs as Collectors Drive Growth March 25, 2024 6:29 AMView eBay Steadily Climbs as Collectors Drive Growth All Headlines Company DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Aprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.IntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.